NEWRON PHARMA N overview

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system, and Myung In Pharm Co. Ltd. (“Myung In Pharm”), South Korea’s leading CNS specialist pharmaceutical company, today announced that they have entered into a license agreement to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate,...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Agreement Newron and Myung In Pharm announce license agreement for evenamide in South Korea 09.01.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron and Myung In Pharm announce license agreement for evenamide in South Korea Myung In Pharm to develop, manufacture and commercialize evenamide in South Korea Myung In Pharm to contribute 10% of patients to Newron’s pivotal Phase III trial for...

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, and EA Pharma Co., Ltd. (Head Office, Chuo-ku, Tokyo, Japan; President, Hidenori Yabune; “EA Pharma”), a subsidiary of Eisai Co., Ltd., today announced that they have entered into a license agreement to develop, manufacture and commercialize Newron’s innovative modulator of...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Agreement Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories 13.12.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories Newron will receive up to a maximum of €117 million from an upfront...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Half Year Results Newron presents H1 2024 results and provides business update 19.09.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron presents H1 2024 results and provides business update Milan, Italy, September 19, 2024, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous Newron Pharmaceuticals reports on its 2024 Investor Day in New York City 25.06.2024 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. Newron Pharmaceuticals reports on its 2024 Investor Day in New York City Clinical results and new findings of mechanism of action indicate evenamide would be uniquely effective in patients with treatment resistant schizophrenia Leading schizophrenia experts...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City 18.06.2024 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City Three of the world’s leading key opinion leaders (KOL) in neuroscience and schizophrenia to review and present findings on Newron’s evenamide program for treatment-resistant...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City 05.06.2024 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City New hope emerges for treatment-resistant schizophrenia: leading KOLs to reveal insights into the neurobiology of treatment for both poorly responding and...